XOMA Corp  

(Public, NASDAQ:XOMA)   Watch this stock  
Find more results for XOMA
4.21
-0.11 (-2.55%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.19 - 4.42
52 week 3.02 - 9.57
Open 4.29
Vol / Avg. 1.05M/2.54M
Mkt cap 449.95M
P/E     -
Div/yield     -
EPS -1.38
Shares 106.88M
Beta 2.77
Inst. own 73%
May 22, 2014
XOMA Annual Shareholder Meeting - 12:00PM EDT - Add to calendar
Mar 11, 2014
XOMA at ROTH Conference
Mar 4, 2014
Q4 2013 XOMA Earnings and Gevokizumab POC Program Update Conference Call - Webcast
Mar 4, 2014
Q4 2013 XOMA Earnings Release
Mar 4, 2014
XOMA at Cowen Health Care Conference
Feb 25, 2014
XOMA at RBC Capital Markets Healthcare Conference
Feb 24, 2014
XOMA at Canaccord Genuity Orphan Drug One-on-One Day
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -417.26% -349.94%
Operating margin -124.30% -164.18%
EBITD margin - -163.26%
Return on average assets -185.81% -103.18%
Return on average equity - -1419.43%
Employees 170 -
CDP Score - -

Address

2910 SEVENTH ST
BERKELEY, CA 94710
United States - Map
+1-510-6441170 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company�s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company�s preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo, named XMet, and represent potential new therapeutic approaches to the treatment of diabetes and several diseases that have insulin involvement. On January 17, 2012, it announced that it had acquired certain the United States rights to a portfolio of antihypertensive products from Servier. The portfolio includes ACEON (perindopril erbumine), a marketed angiotensin converting enzyme (ACE) inhibitor, and three fixed-dose combination (FDC) product candidates where a form of perindopril (perindopril arginine) is combined with another active ingredient.

Officers and directors

W. Denman Van Ness Lead Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
John W. Varian Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Frederick Kurland Chief Financial Officer, Vice President - Finance, Secretary
Age: 62
Bio & Compensation  - Reuters
Patrick J. Scannon M.D., Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 65
Bio & Compensation  - Reuters
Paul D. Rubin M.D. Senior Vice President - Research and Development, Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Tom Klein Chief Commercial Officer
Bio & Compensation  - Reuters
Kelvin M. Neu M.D. Director
Age: 40
Bio & Compensation  - Reuters
William K. Bowes Jr. Independent Director
Age: 86
Bio & Compensation  - Reuters
Peter Barton Hutt Independent Director
Age: 78
Bio & Compensation  - Reuters
Joseph M. Limber Independent Director
Age: 60
Bio & Compensation  - Reuters